California Public Employees Retirement System Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

California Public Employees Retirement System lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 42.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 278,294 shares of the specialty pharmaceutical company's stock after purchasing an additional 83,065 shares during the period. California Public Employees Retirement System owned 0.44% of Jazz Pharmaceuticals worth $34,230,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wedge Capital Management L L P NC increased its holdings in shares of Jazz Pharmaceuticals by 9.2% in the 4th quarter. Wedge Capital Management L L P NC now owns 243,357 shares of the specialty pharmaceutical company's stock worth $29,933,000 after buying an additional 20,587 shares during the last quarter. Duality Advisers LP raised its stake in Jazz Pharmaceuticals by 35.8% during the fourth quarter. Duality Advisers LP now owns 25,641 shares of the specialty pharmaceutical company's stock worth $3,154,000 after purchasing an additional 6,758 shares during the period. abrdn plc increased its stake in Jazz Pharmaceuticals by 442.2% during the 4th quarter. abrdn plc now owns 56,230 shares of the specialty pharmaceutical company's stock worth $6,916,000 after buying an additional 45,860 shares during the period. Waterfront Wealth Inc. grew its holdings in Jazz Pharmaceuticals by 1.2% during the 4th quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company's stock worth $1,062,000 after acquiring an additional 103 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 15.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 4,707 shares of the specialty pharmaceutical company's stock valued at $579,000 after buying an additional 631 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, CFO Philip L. Johnson acquired 12,000 shares of the firm's stock in a transaction on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CAO Patricia Carr sold 1,936 shares of the business's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip L. Johnson bought 12,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $2.03 during midday trading on Friday, hitting $109.46. 480,575 shares of the stock traded hands, compared to its average volume of 504,507. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. The firm has a market capitalization of $6.90 billion, a P/E ratio of 17.89, a PEG ratio of 1.48 and a beta of 0.59. Jazz Pharmaceuticals plc has a one year low of $106.61 and a one year high of $146.70. The firm has a 50-day moving average of $118.25 and a two-hundred day moving average of $121.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. On average, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on JAZZ shares. Robert W. Baird started coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, January 3rd. They issued an "outperform" rating and a $160.00 price target for the company. Barclays dropped their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating on the stock in a research note on Friday, March 1st. UBS Group decreased their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating for the company in a report on Friday, March 1st. Cantor Fitzgerald reissued an "overweight" rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $195.08.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.